| Description | This product is an inhibitory antibody MAA868 that binds the catalytic domain of both zymogen FXI and activated FXI. The antibody has a high affinity for human and cynomolgus monkey FXI and FXIa but not to mouse or rat FXI and FXIa. MAA868 specifically inhibits FXIa function within the intrinsic coagulation pathway. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human, Cynomolgus |
| Epitope | Catalytic domain of FXI and FXIa. |
| IC50 | 13 nM |
| Affinity | Human FXIa: KD = 4.7 pM Human FXI: KD = 1.3 Pm cyno FXIa: KD = 6-19 pM cyno FXI: KD = 4-6 pM |
| Isotype | Human IgG1 |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | Inhib; FuncS |
| Application Notes | MAA868 lengthens aPTT clotting times in a manner that is dependent on its concentration. The IC₅₀ value, which indicates the concentration at which 50% inhibition occurs, is 13 nM. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
